Middle East and Africa Over The Counter Drugs Market - Strategic Insights and Forecasts (2026-2031)

Middle East and Africa Over The Counter Drugs Market is projected to register a strong CAGR during the forecast period (2026-2031).

The increasing prevalence of lifestyle-related ailments, such as type 2 diabetes and hypertension, which drive the need for supportive non-prescription management products, propels demand for OTC drugs in the MEA region. Industry dependency factors are heavily tied to the stability of regional supply chains and the efficiency of local regulatory bodies like the Saudi Food and Drug Authority (SFDA) and South Africa's SAHPRA. Process evolution is evident in the transition toward advanced delivery systems, such as fast-dissolving films and sustained-release formulations, which enhance patient compliance and convenience. Sustainability transitions are increasingly integrated into corporate strategies, with manufacturers adopting eco-friendly packaging and optimizing energy consumption in local production plants to meet national net-zero targets. Regulatory influence remains a critical determinant of market speed, as streamlined classification portals, such as Saudi Arabia’s e-GHAD platform, modernize the path from application to market entry. The strategic importance of the OTC sector lies in its role as a primary cost-saving mechanism for national health budgets, diverting non-emergency cases from clinical settings to self-care.

Market Dynamics

Market Drivers

• Rising Adoption of Self-Medication: Increasing health literacy and the desire for immediate symptom relief drive consumers to choose OTC solutions for minor ailments, thereby reducing outpatient visits and healthcare costs.

• Government-Led Localization Initiatives: Strategic drives in the UAE and Saudi Arabia toward pharmaceutical localization incentivize domestic entities to produce generic and OTC medications, securing the national supply chain against global disruptions.

• Aging Populations and Chronic Ailments: A demographic shift toward older populations, particularly in Israel and parts of the GCC, increases the baseline demand for analgesics and vitamins for chronic symptom management.

• Digital Infrastructure Expansion: The rollout of nationwide digital health portals and e-prescription systems simplifies the classification and availability of OTC products, enhancing consumer accessibility and market transparency.

Market Restraints and Opportunities

• Rigorous Compliance Procedures: Stringent regulatory landscapes regarding advertising and product registration can lead to significant delays in product availability, creating a disconnect between demand and supply.

• Supply Chain Vulnerability: Dependence on imported Active Pharmaceutical Ingredients (APIs) from Asia and Europe exposes the region to logistical bottlenecks and price volatility during global geopolitical shifts.

• E-Commerce and Health-Wellness Growth: The projected expansion of the UAE's health and wellness retail market offers a substantial opportunity for natural and preventive OTC segments.

• Harmonization of Regional Standards: The move toward unified regulatory frameworks across the GCC and African Union (AMLA) presents an opportunity for manufacturers to scale operations more efficiently through mutual recognition agreements.

Raw Material and Pricing Analysis

The primary raw materials for the OTC market consist of APIs (Active Pharmaceutical Ingredients), excipients (binders, fillers, and coatings), and specialized packaging materials like aluminum and PVC for blister packs. API pricing is heavily influenced by the manufacturing output of key global hubs in India and China, where environmental regulations often cause sudden supply tightening. In the MEA region, pricing dynamics are further complicated by regional energy sensitivity and high transportation costs for temperature-sensitive ingredients. Margin management strategies increasingly focus on localizing the production of high-volume ingredients to hedge against currency volatility and international shipping delays. Regional pricing variation is notable; for instance, ex-factory prices in Egypt are often decoupled from local currency fluctuations to maintain operational viability for multinational manufacturers.

Supply Chain Analysis

Production concentration is centered in established pharmaceutical hubs such as Saudi Arabia, the UAE, South Africa, and Egypt, where integrated manufacturing strategies are utilized to maximize output. The supply chain is energy-intensive, requiring specialized HVAC systems and cleanroom environments that are sensitive to regional power stability. Transportation constraints are significant in Sub-Saharan Africa, where underdeveloped logistics infrastructure can increase the cost of last-mile delivery for OTC products. To mitigate regional risk exposure, companies are increasingly investing in localized cold chain technologies and automated warehousing. Furthermore, the shift toward e-pharmacy has necessitated more agile distribution models that can handle high volumes of individual home deliveries while maintaining regulatory compliance.

Government Regulations

Key Developments

• January 2026: Saudi SFDA – Published updated product classification guidance requiring all medicinal claims and ingredient thresholds to be submitted via the e-GHAD platform for annual validation.

• December 2025: SAHPRA – Attained full membership in the International Council for Harmonisation (ICH), marking a major milestone in aligning African pharmaceutical standards with global drug safety benchmarks.

Market Segmentation

By Product Category: Cough, Cold and Flu Products

Cough and cold preparations consistently represent the top therapeutic area in the MEA retail channel, driven by seasonal demand and the high prevalence of respiratory infections. In South Africa, Adcock Ingram leads the market with a 9.3% share, largely supported by its extensive OTC cough and flu portfolio. Structural demand in this segment is reinforced by the accessibility of these products in community pharmacies, where they serve as the first line of defense for non-chronic respiratory symptoms.

By Administration: Oral

The oral administration segment continues to dominate the MEA market due to high patient preference for convenience and the ease of self-administration. Tablets, capsules, and syrups are the primary formats for analgesics and VMS products, which are the highest-selling categories by volume. The operational advantage of oral dosage forms lies in their stability under varied climatic conditions and their suitability for large-scale automated manufacturing in regional plants.

Regional Analysis

In Saudi Arabia, the SFDA’s digital transformation through the e-GHAD platform is the primary driver of market efficiency, allowing for rapid reclassification of products as health or medicinal based on active ingredient thresholds. The Kingdom’s high per-capita spending on vitamins and supplements is a direct result of government health awareness campaigns.

In the UAE, the transition is characterized by a strategic push toward pharmaceutical localization to ensure national drug security, with significant trade deals valued at AED 9.35 billion recorded at the 2025 DUPHAT conference. The market is bolstered by a large expatriate population that favors global OTC brands and high health literacy.

In South Africa, the SAHPRA’s modernization of the regulatory framework is forcing a structural shift toward biopharmaceuticals and standardized generic production. Local giants like Aspen Pharmacare and Adcock Ingram utilize their extensive domestic footprint to hedge against the price volatility of the public tender system.

List of Companies

• Johnson & Johnson (Kenvue)

• Bayer AG

• Sanofi

• Pfizer, Inc.

• Haleon (GlaxoSmithKline plc.)

• Novartis AG

• Boehringer Ingelheim GmbH

• Adcock Ingram

• Aspen Pharmacare

• Julphar (Gulf Pharmaceutical Industries)

Sanofi

Sanofi is the leading corporation in Saudi Arabia, commanding a 6.4% market share and exhibiting a growth rate of 16.6% PPG as of early 2024. The company’s strategy focuses on rapid expansion in the MEA retail channel, particularly through its diversified portfolio of analgesics and cough-cold remedies. Its competitive advantage lies in its deep-rooted regional presence and its ability to maintain high growth rates in volatile markets like West Africa, where it remains the top-selling corporation.

Haleon (Haleon/GSK)

Haleon, the consumer health spin-off of GSK, dominates the Lebanon market with a 10.9% share and achieved significant growth across EMEA and Latin America in 2025. The company’s strategy, "Win as One," prioritizes productivity initiatives and brand resilience to outperform the market in core categories like oral health and analgesics. Haleon’s geographic strength in the Middle East is supported by a robust supply chain that maintains market share even during weak cold and flu seasons.

Bayer AG

Bayer AG utilizes a strategic operating model known as "Dynamic Shared Ownership" to drive operational performance and cash generation across its Consumer Health division. The company is investing over €5 billion annually in R&D to advance its pipeline of "blockbuster" products, including sustainable and digital health innovations. Bayer’s geographic strength in the MEA region is built on iconic brands in the VMS and dermatology segments, which are positioned to meet the growing regional demand for preventive self-care.

Analyst View

Structural demand for OTC drugs in the MEA is driven by government-led localization and rising self-care literacy. While digital transformation and regulatory harmonization offer significant opportunities, currency volatility and import dependencies remain key challenges for long-term regional expansion.

Middle East and Africa Over-The-Counter Drugs Market Scope: